Clinical trials: CMV Infection
Chronic Myeloproliferative Disorders, Leukemia
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
RATIONALE: Tests that measure certain changes in blood in patients at high risk of cytomegalovirus infection may help doctors learn more about predicting cytomegalovirus infection after donor stem cell transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00716911
- Testing
- ganciclovir, polymerase chain reaction, flow cytometry
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infection, Healthy, no Evidence of Disease
Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus
This phase I trial studies the side effects and the best dose of vaccine therapy in healthy volunteers with or without previous exposure to cytomegalovirus.
- Trial name
- NCT01941056
- Testing
- multi-CMV epitope modified vaccinia Ankara vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Arterial Occlusive Diseases, Atherosclerosis
Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction
The purpose of this study is to investigate whether the susceptibility of subjects to atherosclerosis is influenced by prior CMV exposure, whether the susceptability to endothelial dysfunction in patients with and in patients…
- Conditions
- Arterial Occlusive Diseases, Atherosclerosis, Coronary Disease, Cytomegalovirus Infections
- Trial name
- NCT00001531
- Where
- United States
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cytomegalovirus Infections
A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants
The main purpose of the study is to evaluate the safety and immunogenicity of SPYVLP01 in two different doses with and without adjuvants in healthy adults aged 18-50 years old.
- Trial name
- SPYVAC01 (NCT06145178)
- Testing
- SPYVAC01
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- SpyBiotech Limited